Comparable stake leader
FMR LLC
SEC ownership of Cogent Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001622229.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- COGT on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001622229
- Issuer location
- Waltham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Cogent Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
Fairmount Funds Management LLC
8.6%
BlackRock, Inc.
8%
VANGUARD CAPITAL MANAGEMENT LLC
5.1%
TCG Crossover GP I, LLC
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$993,861,419
25,681,174 shares
|
— | 30 Jun 2026 |
| Fairmount Funds Management LLC |
3/4/5
13D/G
13F
Director · Company
|
8.6%
from 13D/G
|
$789,384,787
5,542,832 shares
mixed-class rows
|
-$370,020,000 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
8%
from 13D/G
|
$671,547,401
17,352,646 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.1%
|
$336,364,494
8,691,589 shares
|
$0 | 30 Jun 2026 |
| TCG Crossover GP I, LLC |
13D/G
|
4.8%
|
$97,621,606
6,798,162 shares
|
$0 | 30 Sep 2025 |
| Kynam Capital Management, LP |
13D/G
13F
Company
|
4.3%
|
$219,296,982
6,165,223 shares
|
-$61,214,156 | 31 Dec 2025 |
| Venrock Healthcare Capital Partners II, L.P. |
13D/G
|
4.2%
|
$44,463,093
4,755,411 shares
|
-$15,815,581 | 30 Jun 2025 |
| Point72 Asset Management, L.P. |
13D/G
13F
Company
|
4%
|
$82,625,042
5,753,833 shares
|
-$60,775,814 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$383,888,198.
Buys
$0
Insiders: 0
Sells
$383,888,198
Insiders: 6
Net
-$383,888,198
Shares: -10,860,152
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 10,860,152
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 45,510 | $0 | $1,689,493 | -$1,689,493 |
| 3-6 | 0 | 7,000,000 | $0 | $242,620,000 | -$242,620,000 |
| 6-9 | 0 | 3,814,642 | $0 | $139,578,705 | -$139,578,705 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Cogent Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Fairmount Funds Management LLC
Net 12M change
-$383,888,198
Latest report
27 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director | $789,384,787 | -$370,020,000 | -32% | Mixed | 31 Mar 2026 |
| Andrew R. Robbins | President and CEO, Director | $25,307,290 | Mixed | 19 May 2026 | ||
| Cole Pinnow | Chief Commercial Officer | $8,546,842 | Mixed | 17 Dec 2025 | ||
| John Edward Robinson | Chief Scientific Officer | $5,423,677 | -$3,486,600 | -39% | Filing P/S | 26 Dec 2025 |
| Jessica Sachs | Chief Medical Officer | $5,183,400 | -$3,198,245 | -38% | Filing P/S | 26 Dec 2025 |
| John L. Green | Chief Financial Officer | $5,099,339 | -$2,978,360 | -37% | Filing P/S | 26 Dec 2025 |
| Evan D. Kearns | Chief Legal Officer | $4,233,702 | -$2,515,500 | -37% | Filing P/S | 26 Dec 2025 |
| Arlene Morris | Director | $0 | -$1,689,493 | -100% | Mixed | 27 Aug 2026 |
| Christopher W. Cain | Director | Mixed | 09 Jun 2026 | |||
| Peter Evan Harwin | Director | Mixed | 09 Jun 2026 | |||
| Matthew Ros | Director | Mixed | 09 Jun 2026 | |||
| Karen Jean Ferrante | Director | Mixed | 01 Jul 2026 | |||
| Todd Shegog | Director | Mixed | 09 Jun 2026 |
Recent insider transactions for Cogent Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Arlene Morris | COGT | Common Stock | Sale | -100% | $1,689,493 | $37.12 | -45,510 | 0 | 27 Aug 2026 | Direct |
| Arlene Morris | COGT | Common Stock | Options Exercise | 45,510 | 45,510 | 27 Aug 2026 | Direct | |||
| Arlene Morris | COGT | Stock Option (Right to Buy) | Options Exercise | -100% | -45,510 | 0 | 27 Aug 2026 | Direct | ||
| Karen Jean Ferrante | COGT | Stock Option (Right to Buy) | Award | 627 | 627 | 01 Jul 2026 | Direct | |||
| Peter Evan Harwin | COGT | Stock Option (Right to Buy) | Award | 17,901 | 17,901 | 09 Jun 2026 | Direct | |||
| Karen Jean Ferrante | COGT | Stock Option (Right to Buy) | Award | 17,901 | 17,901 | 09 Jun 2026 | Direct | |||
| Christopher W. Cain | COGT | Stock Option (Right to Buy) | Award | 17,901 | 17,901 | 09 Jun 2026 | Direct | |||
| Todd Shegog | COGT | Stock Option (Right to Buy) | Award | 17,901 | 17,901 | 09 Jun 2026 | Direct | |||
| Arlene Morris | COGT | Stock Option (Right to Buy) | Award | 17,901 | 17,901 | 09 Jun 2026 | Direct | |||
| Matthew Ros | COGT | Stock Option (Right to Buy) | Award | 17,901 | 17,901 | 09 Jun 2026 | Direct | |||
| Andrew R. Robbins | COGT | Common Stock | Gift | 160,000 | 160,000 | 19 May 2026 | By trust | |||
| Andrew R. Robbins | COGT | Common Stock | Gift | -24.3% | -160,000 | 497,503 | 19 May 2026 | Direct | ||
| Karen Jean Ferrante | COGT | Stock Option (Right to Buy) | Award | 686 | 686 | 01 Apr 2026 | Direct | |||
| Fairmount Funds Management LLC | COGT | Common Stock | Sale | -56% | $242,620,000 | $34.66 | -7,000,000 | 5,503,418 | 31 Mar 2026 | Fairmount Healthcare Fund II LP |
| Fairmount Funds Management LLC | COGT | Common Stock | Conversion of derivative security | 127.2% | 7,000,000 | 12,503,418 | 31 Mar 2026 | Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | COGT | Series A Convertible Preferred Stock | Conversion of derivative security | -41.5% | -28,000 | 39,414 | 31 Mar 2026 | Fairmount Healthcare Fund II LP | ||
| Fairmount Funds Management LLC | COGT | Common Stock | Sale | -38.9% | $127,400,000 | $36.40 | -3,500,000 | 5,503,418 | 22 Jan 2026 | Fairmount Healthcare Fund II LP |
| Karen Jean Ferrante | COGT | Stock Option (Right to Buy) | Award | 643 | 643 | 01 Jan 2026 | Direct | |||
| Evan D. Kearns | COGT | Common Stock | Sale | -37.3% | $2,515,500 | $38.70 | -65,000 | 109,398 | 26 Dec 2025 | Direct |
| John L. Green | COGT | Common Stock | Sale | -36.9% | $2,978,360 | $38.68 | -77,000 | 131,834 | 26 Dec 2025 | Direct |
| Jessica Sachs | COGT | Common Stock | Sale | -38.2% | $3,198,245 | $38.70 | -82,642 | 133,938 | 26 Dec 2025 | Direct |
| John Edward Robinson | COGT | Common Stock | Sale | -39.1% | $3,486,600 | $38.74 | -90,000 | 140,002 | 26 Dec 2025 | Direct |
| John Edward Robinson | COGT | Common Stock | Tax liability | -37.8% | -139,998 | 230,002 | 17 Dec 2025 | Direct | ||
| John Edward Robinson | COGT | Common Stock | Award | 370,000 | 370,000 | 17 Dec 2025 | Direct | |||
| John Edward Robinson | COGT | Stock Option (Right to Buy) | Award | 65,000 | 65,000 | 17 Dec 2025 | Direct | |||
| Andrew R. Robbins | COGT | Common Stock | Tax liability | -35.8% | -367,497 | 657,503 | 17 Dec 2025 | Direct | ||
| Andrew R. Robbins | COGT | Common Stock | Award | 1,025,000 | 1,025,000 | 17 Dec 2025 | Direct | |||
| Andrew R. Robbins | COGT | Stock Option (Right to Buy) | Award | 245,000 | 245,000 | 17 Dec 2025 | Direct | |||
| Cole Pinnow | COGT | Common Stock | Tax liability | -30.4% | -94,800 | 216,650 | 17 Dec 2025 | Direct | ||
| Cole Pinnow | COGT | Common Stock | Award | 556.4% | 264,000 | 311,450 | 17 Dec 2025 | Direct | ||
| Cole Pinnow | COGT | Stock Option (Right to Buy) | Award | 65,000 | 65,000 | 17 Dec 2025 | Direct | |||
| Evan D. Kearns | COGT | Common Stock | Tax liability | -41.9% | -125,602 | 174,398 | 17 Dec 2025 | Direct | ||
| Evan D. Kearns | COGT | Common Stock | Award | 300,000 | 300,000 | 17 Dec 2025 | Direct | |||
| Evan D. Kearns | COGT | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 17 Dec 2025 | Direct | |||
| Jessica Sachs | COGT | Common Stock | Tax liability | -41.7% | -154,716 | 216,580 | 17 Dec 2025 | Direct | ||
| Jessica Sachs | COGT | Common Stock | Award | 28549.4% | 370,000 | 371,296 | 17 Dec 2025 | Direct | ||
| Jessica Sachs | COGT | Stock Option (Right to Buy) | Award | 65,000 | 65,000 | 17 Dec 2025 | Direct | |||
| John L. Green | COGT | Common Stock | Tax liability | -41% | -145,007 | 208,834 | 17 Dec 2025 | Direct | ||
| John L. Green | COGT | Common Stock | Award | 9112.2% | 350,000 | 353,841 | 17 Dec 2025 | Direct | ||
| John L. Green | COGT | Stock Option (Right to Buy) | Award | 65,000 | 65,000 | 17 Dec 2025 | Direct | |||
| Karen Jean Ferrante | COGT | Stock Option (Right to Buy) | Award | 1,642 | 1,642 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.